Temozolomide Chronotherapy in Glioma: A Systematic Review

被引:21
|
作者
Jia, Jason L. [1 ]
Alshamsan, Bader [2 ,3 ]
Ng, Terry L. [3 ,4 ]
机构
[1] Univ Ottawa, Dept Med, Core Internal Med Residency Program, Ottawa, ON K1H 8L6, Canada
[2] Qassim Univ, Coll Med, Dept Med, POB 6655, Buraydah, Saudi Arabia
[3] Ottawa Hosp Canc Ctr, Dept Med, Div Med Oncol, Ottawa, ON K1H 8L6, Canada
[4] Ottawa Hosp Res Inst, Canc Therapeut Program, Ottawa, ON K1H 8L6, Canada
关键词
chronotherapy; temozolomide; glioma; glioblastoma; chemotherapy; oncology; ADJUVANT TEMOZOLOMIDE; PHARMACOKINETICS; GLIOBLASTOMA; RADIOTHERAPY; CONCOMITANT; SURVIVAL; TRIAL;
D O I
10.3390/curroncol30020147
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Outcomes for patients with high-grade glioma remain poor. Temozolomide (TMZ) is the only drug approved for first-line treatment of glioblastoma multiforme, the most aggressive form of glioma. Chronotherapy highlights the potential benefit of timed TMZ administration. This is based on pre-clinical studies of enhanced TMZ-induced glioma cytotoxicity dependent on circadian, oscillating expression of key genes involved in apoptosis, DNA damage repair, and cell-cycle mediated cell death. The current systematic review's primary aim was to evaluate the efficacy and toxicity of TMZ chronotherapy. A systemic review of literature following PRISMA guidelines looking at clinical outcomes on TMZ chronotherapy on gliomas was performed. The search in the English language included three databases (PubMed, EMBASE, and Cochrane) and five conferences from 1946 to April 2022. Two independent reviewers undertook screening, data extraction, and risk-of-bias assessment. A descriptive analysis was conducted due to limited data. Of the 269 articles screened, two unique studies were eligible and underwent abstraction for survival and toxicity findings. Both studies-one a retrospective cohort study (n = 166) and the other a prospective randomized feasibility study (n = 35)-were conducted by the same academic group and suggested a trend for improved overall survival, but possibly increased toxicity when TMZ was administered in the morning (vs. evening). There was limited evidence suggesting possible therapeutic value from administering TMZ in the morning, which may be consistent with the pre-clinical observations of the importance of the timing of TMZ administration in vitro. Larger, pragmatic, prospective randomized controlled trials are needed to ascertain the value of TMZ chronotherapy to provide optimized and equitable care for this population.
引用
收藏
页码:1893 / 1902
页数:10
相关论文
共 50 条
  • [21] TEMOZOLOMIDE CHEMOTHERAPY EFFECTS ON GLIOMA PATIENT FERTILITY AND THEIR OFFSPRING: A RETROSPECTIVE REVIEW
    Lu, Austin
    Vu, Mia
    Schuman, Eva
    Ware, Cornelius
    Hsu, Sigmund
    Zhu, Jay-Jiguang
    NEURO-ONCOLOGY, 2024, 26
  • [22] Temozolomide for High Grade Glioma
    Hart, Michael G.
    Grant, Robert
    Garside, Ruth
    Rogers, Gabriel
    Somerville, Margaret
    Stein, Ken
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2008, (04):
  • [23] Temozolomide for high grade glioma
    Hart, Michael G.
    Garside, Ruth
    Rogers, Gabriel
    Stein, Ken
    Grant, Robin
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (04):
  • [24] Rechallenge with temozolomide in recurrent glioma
    Gaviani, P.
    Silvani, A.
    Lamperti, E.
    Botturi, A.
    Fariselli, L.
    Simonetti, G.
    Ferrari, D.
    Salmaggi, A.
    NEUROLOGICAL SCIENCES, 2011, 32 : S247 - S249
  • [25] Temozolomide and treatment of malignant glioma
    Friedman, HS
    Kerby, T
    Calvert, H
    CLINICAL CANCER RESEARCH, 2000, 6 (07) : 2585 - 2597
  • [26] Rechallenge with temozolomide in recurrent glioma
    P. Gaviani
    A. Silvani
    E. Lamperti
    A. Botturi
    L. Fariselli
    G. Simonetti
    D. Ferrari
    A. Salmaggi
    Neurological Sciences, 2011, 32 : 247 - 249
  • [27] SUPRATOTAL RESECTION IN GLIOMA: A SYSTEMATIC REVIEW
    de Leeuw, Charles
    Vogelbaum, Michael
    NEURO-ONCOLOGY, 2018, 20 : 255 - 255
  • [28] Lipid Alterations in Glioma: A Systematic Review
    Rashid, Khairunnisa Abdul
    Ibrahim, Kamariah
    Wong, Jeannie Hsiu Ding
    Ramli, Norlisah Mohd
    METABOLITES, 2022, 12 (12)
  • [29] Brainstem Glioma in Pregnancy: A Systematic Review
    Rosen, Adam
    Anderson, Valerie
    Bercovic, Eduard
    Laperriere, Normand
    D'Souza, Rohan
    OBSTETRICS AND GYNECOLOGY, 2018, 131 : 153S - 153S
  • [30] Supratotal resection in glioma: a systematic review
    de Leeuw, Charles N.
    Vogelbaum, Michael A.
    NEURO-ONCOLOGY, 2019, 21 (02) : 179 - 188